Table 2 Headache characteristics at baseline of the total cohort and the subgroups of patients suffering from migraine, tension-type headache (TTH), migraine and TTH and medication-overuse headache (MOH) and assignement to treatment modules
From: Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study
|  | Total | Migraine | TTH | Migraine + TTH | MOH |
|---|---|---|---|---|---|
Number of patients | 204 | 62 | 11 | 59 | 69 |
Duration of disease, Months, mean (SD) | 240.4 ± 153.5 | 229.3 ± 151.7 | 141.8 ± 118.2 | 224.9 ± 137.2 | 279.8 ± 163.7 |
Headache frequency, days/month (SD) | 14.5 ± 8.2 | 8.9 ± 4.3 | 15.3 ± 5.5 | 13.1 ± 7.5 | 19.6 ± 7.5 |
Intake frequency of attack-aborting medication, days/month (SD) | 10.3 ± 7.3 | 6.7 ± 3.2 | 5.1 ± 3.5 | 6.9 ± 3.9 | 17.5 ± 7.3 |
Missed school-/workdays/3 month | 24.6 ± 32.3 | 18.7 ± 18.9 | 16.3 ± 34.5 | 19.8 ± 20.7 | 35.2 ± 45.8 |
Experience with non-pharmacological treatment (%) | 37.9 | 40.3 | 27.3 | 47.5 | 36.2 |
MIDAS, mean (SD) | 51.94 ± 56.95 | 39.53 ± 35.89 | 43.1 ± 79.1 | 45.55 ± 46.22 | 70.53 ± 73.00 |
HADS-depression, mean (SD) | 5.29 ± 3.90 | 4.34 ± 3.55 | 5.00 ± 5.64 | 5.29 ± 3.61 | 6.38 ± 3.99 |
HADS-anxiety, mean (SD) | 7.02 ± 4.16 | 6.00 ± 3.33 | 5.67 ± 5.45 | 7.65 ± 3.93 | 7.83 ± 4.72 |
SF 12—physical (SD) | 40.75 ± 8.63 | 41.64 ± 7.74 | 42.80 ± 9.98 | 43.02 ± 8.56 | 38.02 ± 8.45 |
SF 12—mental (SD) | 44.34 ± 10.61 | 47.09 ± 9.45 | 46.55 ± 13.94 | 44.38 ± 10.88 | 41.67 ± 10.31 |